Floatz logo

Brexpiprazole

Depressive Disorder

Dr. Albert Kar-Kin ChungSmall moleculePhase 4 / ApprovedActive
A
82/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
74/ 100
Competitive Position
95/ 100

Competitive context

77 Active assets in the Depressive Disorder cohort.

Asset / SponsorPhaseRating
Jnj-54135419
Chinese PLA General Hospital
Phase 4BBB
Saredutant
Sanofi
Phase 3BBB
Paroxetine
Brigham and Women's Hospital
Phase 4BBB
VENLOR
Janssen Research & Development, LLC
Phase 4BBB
Fluoxetine
University of Oxford
Phase 4BBB

View all 50 →

Same molecule, other indications

Brexpiprazole is also rated in:

schizophreniaActive
BBB
Indicative · Phase 4
75 / 100
View asset →
major depressive disorderActive
BBB
Indicative · Phase 4
75 / 100
View asset →
mood disorderDormant
BBB
Indicative · Phase 3
75 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →